CDEK
← All drugs Report issue

idebenone

Small moleculeexperimental

Idebenone, sold under the brand name Raxone among others, is a medication that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects. This has been met with limited success. The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich's ataxia and Duchenne muscular dystrophy have been completed. As of December 2013 the drug is not approved for these indications in North America or Europe. It is approved by the European Medicines Agency (EMA) for use in Leber's hereditary optic neuropathy (LHON) and was designated an orphan drug in 2007. — Wikipedia

Clinical trial activity

30 trials · 30 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
20
Phase 3
11
Phase 4
4

Earliest trial started May 1, 2001 (NCT00015808)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2006

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetOTHER

    Antioxidant and mitochondrial electron carrier

  • Unspecified targetAntioxidant

    antioxidant

Chemistry & pharmacology

Loading structure…

SMILES

NS(=O)(=O)c1ccc(NCc2ccccc2)cc1
Mol. weight
262.33 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone
  • 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone
  • 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
  • 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
  • 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
  • 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
  • 2,3-dimethoxy-5-methyl-6-(10'-hydroxydecyl)-1,4-benzoquinone
  • 2,3-dimethoxy-5-methyl-6-(10'-hydroxydecyl)-1,4-benzoquinone
  • 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone
  • 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone
  • 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-p-benzoquinone
  • cv 2619
  • cv 2619
  • cv-2619
  • cv-2619
  • daruma
  • hydroxydecyl ubiquinone
  • hydroxydecyl ubiquinone
  • hydroxydecyl ubiquinone
  • hydroxydecyl ubiquinone
  • hydroxydecyl ubiquinone
  • hydroxydecyl ubiquinone
  • idebenone
  • idebenone
  • idebenone
  • idebenone
  • idebenone
  • idebenone
  • idebenone
  • idebenone
  • idebenone
  • idebenone
  • idébénone
  • idébénone
  • noben
  • raxone
  • raxone
  • raxone

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05987397Phase 4Jul 5, 2023Central South University
NCT05411978Phase 4May 9, 2022Capital Medical University
NCT04669158Phase 1/Phase 2 (Phase 2)Mar 31, 2021National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Stanford University
NCT04534023Phase 2Sep 1, 2020Huazhong University of Science and Technology, Jiao Tong University, Soochow University
NCT04152655Phase 2/Phase 3 (Phase 3)Jan 1, 2020Zhejiang University
NCT04151472Phase 3Nov 30, 2019Zhejiang University
NCT03727295Phase 4Jan 1, 2019Qilu Pharmaceutical Co., Ltd., Soochow University
NCT03603288Phase 3Jul 4, 2018Santhera
NCT02887443Phase 1Sep 1, 2016Santhera
NCT02814019Phase 3Sep 1, 2016Santhera
NCT02774005Phase 4May 1, 2016Santhera
NCT01854359Phase 1/Phase 2 (Phase 2)Feb 22, 2013National Institute of Neurological Disorders and Stroke (NINDS)
NCT01495715Phase 3Dec 16, 2011Santhera
NCT01303406Phase 3Apr 1, 2011Santhera, University of London
NCT00950248Phase 1/Phase 2 (Phase 2)Jul 20, 2009National Institute of Neurological Disorders and Stroke (NINDS)
NCT01027884Phase 3Jul 1, 2009Fondazione IRCCS Eugenio Medea, Karolinska Institute, Katholieke Universiteit Leuven, Leiden University, Methodist Cancer Center, Houston, Texas, Santhera, The Charlotte-Mecklenburg Hospital Authority, The University of Texas, Dallas, Universidad Complutense de Madrid, University of California, Davis, University of Colorado, University of Florida, University of Milan, University of Pennsylvania, University of Washington, Vanderbilt University
NCT00887562Phase 2May 1, 2009Columbia University, Santhera
NCT00758225Phase 2Sep 1, 2008Katholieke Universiteit Leuven, Santhera
NCT00697073Phase 3Jul 1, 2008Santhera, University of California, Los Angeles, University of Pennsylvania
NCT00537680Phase 3Dec 1, 2007Santhera, University of California, Los Angeles, University of Pennsylvania
Showing 20 of 30 trials
Page 1 / 2

Organizations

Research & Development (30)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
SantheraFor profit171652005
National Institute of Neurological Disorders and Stroke (NINDS)Government5522001
Katholieke Universiteit LeuvenAcademic/Hospital3022005
University of LondonAcademic/Hospital3012006
University of PennsylvaniaAcademic/Hospital3012007
Soochow UniversityAcademic/Hospital2122019
University of California, Los AngelesAcademic/Hospital2012007
Zhejiang UniversityAcademic/Hospital2212019
Capital Medical UniversityAcademic/Hospital1112022
Central South UniversityAcademic/Hospital1112023
Columbia UniversityAcademic/Hospital1112009
Fondazione IRCCS Eugenio MedeaAcademic/Hospital1012009
Huazhong University of Science and TechnologyAcademic/Hospital1012020
Jiao Tong UniversityAcademic/Hospital1112020
Karolinska InstituteAcademic/Hospital1012009
Leiden UniversityAcademic/Hospital1012009
Methodist Cancer Center, Houston, TexasAcademic/Hospital1012009
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government1012021
Qilu Pharmaceutical Co., Ltd.For profit1012019
Stanford UniversityAcademic/Hospital1112021
30 organizations
Page 1 / 2